1. Cardiac safety investigations 10 years after ICH guidance E14: evolving industry and regulatory viewpoints on evaluation of proarrhythmic risk during new drug development;Kothari;J Clin Stud.,2015
2. Reducing QT liability and proarrhythmic risk in drug discovery and development;Valentin;Br J Pharmacol,2010
3. ICH Harmonized Tripartite Guideline The clinical evaluation of QT/QTc interval prolongation and proarrhythmic potential for non-antiarrhythmic drugs E14 2005 http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Efficacy/E14/E14_Guideline.pdf
4. Automated QT interval measurements in 12-lead digital Holter ECGs: a comparison of ECGs sampled at 180 Hz and 1000 Hz;Panicker;Comput Cardiol,2010
5. Update on the evaluation of a new drug for effects on cardiac repolarization in humans: issues in early drug development;Salvi;Br J Pharmacol,2010